Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

Gain expert insights on when to use therapeutic drug monitoring proactively to improve the efficacy of biologic therapy for IBD and reactively to guide decision-making following primary nonresponse or secondary loss of response to a biologic.


Provided by

ProCE Banner

Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options.


Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Pharmaceuticals U.S.A., Inc.